DNA Methylation Biomarkers in Cancer: Progress Towards Clinical Implementation

Mikeska, Thomas; Bock, Christoph; Do, Hongdo; Dobrovic, Alexander

doi:10.1586/erm.12.45

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

DNA Methylation Biomarkers in Cancer: Progress Towards Clinical Implementation

MPS-Authors

/persons/resource/persons44148

Bock, Christoph
Computational Biology and Applied Algorithmics, MPI for Informatics, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Mikeska, T., Bock, C., Do, H., & Dobrovic, A. (2012). DNA Methylation Biomarkers in Cancer: Progress Towards Clinical Implementation. Expert Review of Molecular Diagnostics, 12(5), 473-487. doi:10.1586/erm.12.45.

Cite as: https://hdl.handle.net/11858/00-001M-0000-0014-C824-4

Abstract

Altered DNA methylation is ubiquitous in human cancers and specific methylation changes are often correlated with clinical features. DNA methylation biomarkers, which use those specific methylation changes, provide a range of opportunities for early detection, diagnosis, prognosis, therapeutic stratification and post-therapeutic monitoring. Here we review current approaches to developing and applying DNA methylation biomarkers in cancer therapy. We discuss the obstacles that have so far limited the routine use of DNA methylation biomarkers in clinical settings and describe ways in which these obstacles can be overcome. Finally, we summarize the current state of clinical implementation for some of the most widely studied and well-validated DNA methylation biomarkers, including SEPT9, VIM, SHOX2, PITX2 and MGMT.